

1 **Safety and immunopotency of an adenovirus-vectored tuberculosis vaccine delivered via**
2 **inhaled aerosol to healthy humans: a dose and route comparison phase 1b study**

3
4 Mangalakumari Jeyanathan,^{1,2,3} Dominik K. Fritz,^{1,2,3} Sam Afkhami,^{1,2,3} Emilio Aguirre,⁴ Karen J.
5 Howie,³ Anna Zganiacz,^{1,2,3} Anna Dvorkin-Gheva,^{1,3} Michael R. Thompson,⁵ Richard F. Silver,⁶
6 Ruth P. Cusack,³ Brian D. Lichty,^{1,3} Paul M. O’Byrne,³ Martin Kolb,³ Maria Fe C. Medina,^{1,3}
7 Myrna B. Dolovich,³ Imran Satia,³ Gail M. Gauvreau,³ Zhou Xing,^{1,2,3*} & Fiona Smail^{2,4*}

8
9 ¹McMaster Immunology Research Centre, ²M. G. DeGroote Institute for Infectious Disease
10 Research, ³Department of Medicine, ⁴Department of Pathology & Molecular Medicine, and
11 ⁵Department of Chemical Engineering, McMaster University, Hamilton, Ontario, Canada;
12 ⁶Department of Critical Care and Sleep Medicine, Case Western Reserve University School of
13 Medicine, Cleveland, Ohio, USA

14
15 ***Joint lead & correspondence contacts:** xingz@mcmaster.ca (Z. Xing), smail@mcmaster.ca (F.
16 Smail)

17
18
19
20
21
22
23
24
25
26
27

28 Summary

29 **Background** Adenoviral (Ad)-vectored vaccines are typically administered via intramuscular
30 injection to humans, but this route of delivery is unable to induce respiratory mucosal immunity
31 which requires respiratory mucosal route of vaccination. However, inhaled aerosol delivery of Ad-
32 vectored vaccines has remained poorly characterized and its ability to induce respiratory mucosal
33 immunity in humans is still unknown. The goal of our study was to evaluate and compare the
34 safety and immunogenicity of a human serotype 5 Ad-based tuberculosis (TB) vaccine
35 (AdHu5Ag85A) delivered to healthy humans via inhaled aerosol or intramuscular injection.

36
37 **Methods** In this open-labeled phase 1b trial, 31 healthy adults between 18 and 55 years of age
38 with a history of BCG vaccination were enrolled at McMaster University Medical Centre,
39 Hamilton, Ontario, Canada. AdHu5Ag85A was administered by a single-dose aerosol using the
40 Aeroneb® Solo Vibrating Mesh Nebulizer or by intramuscular (IM) injection; 11 in the low dose
41 (LD, 1×10^6 PFU) aerosol group, 11 in the high dose (HD, 2×10^6 PFU) aerosol group and 9 in the
42 IM (1×10^8 PFU) group. The primary outcome was safety of a single administration of vaccine
43 delivered to the respiratory tract by aerosol or by IM injection. The vaccine-related local and
44 systemic adverse events were collected from participants from a self-completed diary for 14 days
45 after vaccination and at scheduled follow-up visits. Routine laboratory biochemical and
46 haematological tests were measured at 2, 4 and 12 weeks after vaccination and lung function was
47 measured at 2, 4, 8 and 12 weeks after vaccination. The secondary outcome was comparison of
48 immunogenicity among the different routes and aerosol dose groups. Immunogenicity to aerosol
49 or IM vaccination was measured both in the peripheral blood and bronchoalveolar lavage samples
50 by Luminex, and cell surface and intracellular cytokine immunostaining. Anti-AdHu5 antibodies
51 and neutralization titers were determined before and after vaccination using ELISA and bioassay,
52 respectively. This trial is registered with ClinicalTrial.gov, NCT02337270.

53 **Results** The aerosol droplets generated by Aeroneb® Solo Nebulizer were mostly $< 5.39 \mu\text{m}$ in size,
54 suitable for efficient Ad-vectored vaccine deposition to major human airways. Both LD and HD
55 of AdHu5Ag85A administered by aerosol inhalation and the intramuscular injection were safe and
56 well-tolerated. Respiratory adverse events were infrequent, mild, transient and similar among
57 groups. IM injection was associated with a mild local injection site reaction in two participants.
58 Systemic adverse events were also infrequent, mild, transient and similar among all groups. There
59 were no grade 3 or 4 adverse events reported nor any serious adverse events. Both aerosol doses,
60 particularly LD, but not IM, vaccination markedly induced Ag85A-specific airway tissue-resident
61 memory CD4 and CD8 T cells of polyfunctionality. While as expected, IM vaccination induced
62 Ag85A-specific T cell responses in the blood, the LD aerosol vaccination also elicited such T cells
63 in the blood. Furthermore, the LD aerosol vaccination induced persisting transcriptional changes
64 in alveolar macrophages indicative of trained innate immunity.

65
66 **Interpretation** Inhaled aerosol delivery of Ad-vectored vaccine is a safe, economical and superior
67 way to elicit respiratory mucosal immunity. The results of this study encourage further
68 development of aerosol vaccine strategies against not only TB but also other respiratory pathogens
69 including COVID-19.

70
71 **Funding** The Canadian Institutes for Health Research and the Natural Sciences and Engineering
72 Research Council of Canada.

73 **Research in context**

74

75 ***Evidence before this study***

76 We searched PubMed for published research articles without language or date restrictions by using
77 search terms “adenovirus”, “aerosol” and “clinical trial” or “virus”, “vaccine”, “aerosol”, and
78 “clinical trial”. Our search results indicate that adenoviral-vectored vaccine has rarely been
79 delivered via inhaled aerosol into the respiratory tract of healthy humans. Adenoviral-vectored TB
80 or HIV vaccine was delivered via inhaled aerosol to non-human primates, providing support for
81 its further development for human application. An aerosolized adenoviral vector expressing CFTR
82 was tested as a gene replacement therapeutic in cystic fibrosis patients. Recently, although an
83 adenoviral-vectored COVID-19 vaccine was delivered via aerosol to humans, there were no
84 evidence presented that it induced local mucosal immunity. Given the increased recognition of its
85 value, inhaled aerosol has been explored in humans with non-adenoviral, viral vaccines against
86 respiratory infections of global importance including measles and TB. However, since different
87 aerosol technologies were used in these studies and aerosol characteristics including delivery
88 efficiency vary according to the viral platform, aerosol delivery technology and its efficiency in
89 inducing respiratory mucosal immunity remain to be established for administering adenoviral-
90 vectored vaccine to healthy humans.

91

92 ***Added value of this study***

93 This represents the first study to demonstrate the characteristics of a single-dose aerosolized human
94 serotype 5 adenoviral-vectored vaccine, and its safety and immunogenicity in BCG-vaccinated
95 healthy humans. It is also the first to show the superiority of inhaled aerosol immunization with
96 this type of vaccine platform, over intramuscular (IM) route of immunization, in inducing
97 respiratory mucosal immunity. Robust adaptive immune memory responses were induced in the
98 respiratory tract with an aerosol vaccine dose up to 100 times smaller than the dose for IM
99 immunization. Besides local mucosal immunity induced by aerosol immunization, it also induces
100 levels of systemic immunity comparable to those by IM immunization. Also for the first time, we
101 show that contrast to IM immunization, aerosol immunization does not increase either local or
102 systemic anti-adenoviral neutralizing antibodies.

103

104 ***Implications of all the available evidence***

105 Collectively our findings show the technical feasibility, safety and potency of needle/pain-free
106 delivery of a recombinant adenoviral-vectored vaccine to the respiratory tract of healthy adults.
107 This vaccine strategy differs from parenteral route of immunization in its potency to elicit much
108 desired respiratory mucosal immunity consisting of trained macrophages and tissue-resident
109 memory T cells. The study provides the proof of concept to endorse inhaled aerosol vaccine
110 strategies against pulmonary TB. Of further importance, as a number of currently authorized
111 COVID-19 vaccines are also adenoviral-vectored, our study offers important technological details
112 and scientific rationale for the development of inhalable next-generation COVID-19 vaccines
113 aiming to induce all-around protective respiratory mucosal immunity in humans.

114

115

116

117 **Introduction**

118 Pulmonary tuberculosis (TB) continues to be a major global health issue, accounting for
119 1.4M deaths and 10M new cases in 2019¹. BCG, as the most administered human vaccine which
120 is given via the skin shortly after birth, has failed to effectively control TB in adults. A safe and
121 effective boost vaccine strategy is urgently needed for much improved protective immunity in the
122 lung^{2,3}.

123 Among the promising vaccine platforms is a recombinant replication-defective human
124 serotype 5 adenoviral-vectored TB vaccine expressing *M.tb* antigen 85A (AdHu5Ag85A). This
125 vaccine has been extensively evaluated in a number of preclinical models, shown to be highly
126 effective when administered via the respiratory tract, as opposed to its parenteral delivery^{3,4}.
127 Besides its superior effects in inducing lung tissue-resident memory T cells³, respiratory mucosal-
128 delivered AdHu5Ag85A is able to elicit long-lasting memory airway macrophages and trained
129 innate immunity^{5,6}. It is widely believed that the most effective vaccine strategy ought to induce
130 both innate memory and adaptive memory responses^{5,7}. Although AdHu5Ag85A was evaluated
131 successfully in healthy humans following intramuscular injection^{8,9}, its suitability for respiratory
132 mucosal delivery and its safety and immunogenicity remain to be determined in BCG-vaccinated
133 healthy humans.

134 Recent studies have shown inhaled aerosol to be a safe and effective delivery method for
135 respiratory mucosal route of immunization in healthy humans with measles and MVA85A
136 vaccines¹⁰⁻¹³. However, these studies applied different technologies for aerosol delivery. Since
137 aerosol characteristics and delivery efficiency may vary according to the type of vaccine, an
138 aerosol delivery technology remains to be characterized and validated for administering
139 adenoviral-vectored vaccine to the human airway. Although an adenoviral-vectored COVID-19
140 vaccine was delivered via aerosol to humans in a recent clinical trial¹⁴, unfortunately its ability
141 and advantage to induce respiratory mucosal immunity was not assessed and thus remains
142 unknown. Given that a number of currently approved COVID-19 vaccines are also based on
143 adenoviral vector, it is highly relevant to fully characterize an inhaled aerosol delivery technology
144 for adenoviral-vectored vaccine and investigate its ability to induce respiratory mucosal immunity
145 in preparation for its translation to respiratory mucosal COVID-19 vaccine strategies¹⁵. Such next-
146 generation COVID-19 vaccine strategies are urgently needed in the face of increasing break-
147 through infections due to the variants of concern and waning vaccine-induced immunity¹⁶.

148 In the present phase 1b study, we have characterized the property of AdHu5Ag85A aerosol
149 droplets generated by the AeroNeb Solo nebulizer. We evaluated the two aerosol doses and
150 compared the safety and immunogenicity of the vaccine delivered via the respiratory mucosal route
151 or intramuscular route in previously BCG-vaccinated healthy adults. Our study is the first to safely
152 deliver an adenovirus-vectored vaccine via inhaled aerosol to humans and to demonstrate its
153 superiority in inducing respiratory mucosal immunity over intramuscular injection.

154

155 **Methods**

156 Study design and participants

157 This was an open-labeled phase 1 trial investigating a single recombinant genetic TB
158 vaccine AdHu5Ag85A in healthy subjects with a history of BCG vaccination. The vaccine was
159 administered as a single dose either by inhaled aerosol or by intramuscular (IM) injection. Study
160 participants were recruited by advertising, approved by the local REB. BCG (+) status was
161 determined based on patient/parent recall, vaccination records, or birth country where BCG
162 vaccine is routinely administered (Fig 1). All enrolled participants were healthy and had normal
163 baseline hematology, spirometry and DLCO, biochemistry, chest X-ray and negative serological
164 testing for HIV antibody. Latent *Mtb* infection was excluded by a negative interferon gamma
165 release assay. Current smokers and ex-smokers who had quit within the last year, people with a
166 history of inhaled recreational drugs, respiratory disease, e.g., asthma, chronic obstructive
167 pulmonary disease (COPD), and pregnant or lactating women were excluded. Following
168 vaccination, participants were asked to record their temperature twice a day daily at set times for
169 5 days and kept a diary to record any symptoms they experience for 14 days. Safety and medical
170 evaluation was performed at baseline, and 48-72 hours, 2, 4, 8, 12, 16 and 24 weeks after vaccine
171 administration. Adverse events were assessed according to the CTCAE Expanded Common
172 Toxicity Criteria. Immunological evaluation was performed with bronchoalveolar lavage and
173 blood samples. Bronchoscopy was carried out within 1 to 6 days before planned vaccination and
174 at both 2 and 8 weeks post-vaccination. Blood samples were collected at baseline and at 2, 4, 8
175 and 12 weeks post-vaccination.

176 All participants provided written informed consent. This phase 1 trial was approved by the
177 Health Canada and Hamilton Integrated Research Ethics Board. This trial is registered with
178 ClinicalTrial.gov, number NCT# 02337270.

179 Randomization and masking

180 The first cohort of 8 BCG positive subjects received 10^6 pfu (vp/pfu ratio: 32)(low dose-
181 LD) AdHu5Ag85 vaccine administered by aerosol. The second cohort consisted of 18 participants
182 randomly allocated to receive either 2×10^6 pfu (high dose-HD) by aerosol (n=9) or single
183 intramuscular administration of 10^8 pfu (IM) AdHu5Ag85 vaccine (n=9). For the second cohort,
184 a randomization list was generated containing sequential codes linked to route of study vaccine
185 assignment, either IM injection or aerosol (Fig 1). Following a review of the data after the
186 enrolment of the second cohort, the protocol was amended, and an additional 3 participants were
187 enrolled in the high dose aerosol group and an additional 3 participants were enrolled in the low
188 dose group. The study was not blinded. Each participant served as their own control (before and
189 after vaccination) and there was no placebo group. For safety reasons, 2 participants were first
190 vaccinated for each aerosol dose, and followed for 2 weeks after vaccine administration before
191 immunizing the rest of the participants in the dose group. Reports detailing AEs and SAEs for 4
192 weeks post-dose were reviewed by the safety monitoring committee before moving to the higher
193 dose. All participants were followed for a total of 24 weeks after vaccine administration.

194 Procedures

195 The Aeroneb® Solo Micropump was selected as the delivery device (Fig S1). The aerosol
196 performance of the Aeroneb® Solo Vibrating Mesh Nebulizer with AdHu5Ag85A was
197 characterized using standard procedures and performance metrics¹⁷. Fill volume (FV), delivery
198 time, emitted dose (ED) of vaccine aerosol available at the mouth collected on standard filters,
199 aerosol droplet size characteristics using the NGI Cascade Impactor operated at 15Lpm were
200 measured. Salbutamol sulphate served as the tracer for saline droplets containing vaccine particles.
201 Regional deposition of vaccine droplets in the lung was estimated from the particle size metrics of
202 the carrier (salbutamol) aerosol. An indication of the available vaccine dose at the mouth was
203 predicted from ED. The amount of aerosol-containing vaccine estimated to be deposited into the
204 lung was calculated using ED in combination with particle size statistics. Viability of the
205 aerosolized vaccine was determined by plaque forming assay.

206 Clinical grade AdHu5Ag85A vaccine was provided by the Robert E Fitzhenry Vector
207 Laboratory, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario,
208 Canada. AdHu5Ag85A was produced according to current Good Manufacturing Practices (cGMP)
209 in the Vector Laboratory and has been fully certified. For each participant allocated to receive
210 vaccine by aerosol, a single dose of AdHu5Ag85A diluted in 0.5 ml saline was aerosolized using
211 the Aeroneb Solo and inhaled via mouthpiece using tidal breathing. For participants allocated to
212 receive IM route, AdHu5Ag85A diluted in 0.5 ml saline was injected as described previously ⁸.

213 Bronchoscopy was performed using a flexible bronchoscope, with the procedure
214 performed in the research facility at the Health Science Centre, McMaster University by a trained
215 respiratory physician. Following light sedation (using midazolam and fentanyl) and local
216 anaesthesia to the upper and lower respiratory tract, the bronchoscope was advanced until wedged
217 in the right middle bronchus and approximately 40ml of sterile saline instilled and then aspirated
218 back using gentle manual suction in a 50 ml syringe. This was sequentially repeated an additional
219 3 times with a total of 160 ml of saline lavage. Oxygen saturations were monitored throughout the
220 whole procedure. After the bronchoscopy, vital signs (SaO₂, HR, BP) were measured immediately,
221 15 mins, 30 mins, 45 mins, 60 mins and 2 hours during recovery. Spirometry was repeated to
222 ensure FEV₁>70% predicted and within 15% of pre-bronchoscopy values before discharge. Each
223 aspirate was kept separate on ice and processed within an hour after collection at McMaster
224 Immunology Research Center. The first aspirate was discarded after obtaining the cell count. 2nd,
225 3rd and 4th BALF was saved separately and stored at -80°C for future analysis. Cells were then
226 pooled and counted.

227 Interferon gamma release assay was performed using QuantiFERON TB Gold in tube or
228 QuantiFERON TB Gold Plus (Qiagen) according to manufacturer's instruction to determine latent
229 TB status ⁸. Collected serum and concentrated BALF samples (20-fold concentrated from 10 ml
230 of combined aspirates 2 and 3 using Centriprep 3kDa Cut-off centrifugal filter unit-Millipore-
231 Sigma) were measured for anti-AdHu5 IgG antibodies as previously described ⁸. AdHu5-
232 neutralizing antibody (nAb) levels in serum and concentrated BALF were assessed as a function
233 of GFP-expressing AdHu5 infection using A549 cells as previously described ¹⁸. For both total
234 IgG and nAb titers, serum samples at a 1:10 and BALF at a 1:5 dilution were used.

235 We counted the total cells in the BALF and calculated the number of cells per ml of BALF.
236 Differential cell count was performed on the cells from BALF using cytoSpin. We quantified the
237 Ag85A- and *M.tb* antigen-specific T cell responses in the peripheral blood and in the airways
238 represented by the BALF using ELISA and/or intracellular cytokine staining (ICS) assay as
239 previously described⁸. Antigens used for stimulation included the pooled Ag85A overlapping
240 peptides (Ag85A p. pool) and a cocktail of mycobacterial antigens consisting of *M.tb* culture
241 filtrate proteins (*M.tb*CF) and recombinant Ag85A protein (rAg85A) at concentrations previously
242 described⁸. Unstimulated and PHA-stimulated cells were set up in parallel as background and
243 positive controls. For whole blood culture and the ELISA, 1 ml of heparinized whole blood was
244 added into each well of a 24-well plate. Each was stimulated for 18 to 24 hours with one of the
245 antigens mentioned above. Collected plasma was stored at -70°C . Cytokines were determined for
246 human $\text{IFN}\gamma$, IL-2, and $\text{TNF}\alpha$ using Luminex Multiplex Kit from Millipore. Fresh PBMC and
247 BALF cells were stimulated with antigens and wells were processed according to manufacturer's
248 instruction (BD Biosciences).

249 For determination of CD4 and CD8 T cell responses to vaccine using the whole blood
250 culture¹⁰, 1ml of blood was stimulated with each of the antigens mentioned above in the presence
251 of $1\ \mu\text{g}/\text{mL}$ $\alpha\text{CD}28$, $1\ \mu\text{g}/\text{mL}$ $\alpha\text{CD}49\text{d}$ (BD Biosciences). Samples were incubated at 37°C in 5%
252 CO_2 for 6h with Ag85A p. pool or PHA stimulation or for 12h with *Mtb*CF-rAg85A stimulation.
253 Brefeldin-A was added for last 5h (Ag85A p. pool or PHA) or last 6h (*Mtb*CF-rAg85A or
254 unstimulated whole blood). At the end of incubation, red blood cells were lysed, and samples were
255 frozen in liquid nitrogen until FACS analysis. To determine the CD4 and CD8 T cell responses in
256 the airways, $0.5\text{-}1 \times 10^6$ BALF cells were plated and stimulated as for the whole blood. At the end
257 of incubation, cells were immediately stained for ICS and FACS analysis.

258 Surface immunostaining and ICS was done as previously described⁸. Briefly, frozen cells
259 from whole blood were thawed and permeabilized before staining with a cocktail of fluorochrome-
260 conjugated monoclonal antibodies; CD3 (FITC), CD4 (PB), CD8 (PECy7), $\text{IFN}\gamma$ (PE), IL-2 (APC),
261 and $\text{TNF}\alpha$ (PerCP-Cy5.5). BALF cells were surface-immunostained for viability (Molecular
262 Probes LIVE/DEAD fixable stain (Aqua), Invitrogen) followed by CD4 (AF700), CD14 (V450),
263 CD19 (V450). Cells were then permeabilized and stained for intracellular cytokines $\text{IFN}\gamma$ (PE),
264 IL-2 (APC), and $\text{TNF}\alpha$ (FITC). Ag85A p. pool-stimulated whole blood and BALF cells were also

265 stained for surface markers CD103 (APC), CD69 (PerCP-Cy5.5) and CD49d (PE-dazzle) to
266 evaluate the surface expression of tissue-resident memory T cell- or T cell lung trafficking-
267 associated molecules. Cells were analyzed with LSRII flow cytometer and assessed with Flowjo
268 version 9.9.6 (Tree Star Inc.).

269 We evaluated the induction of trained innate immunity in airway macrophages in the LD
270 dose group. After reviving the frozen BALF cells for 6h, one million viable cells were seeded on
271 a 12-well plate and incubated for 2h at 37°C, 5% CO₂. At this point, airway macrophages were
272 enriched by removal of non-adherent cells via extensive washing with pre-warmed (37°C) PBS
273 and then cultured with or without *M.tb* lysates stimulant for 12h. Total RNA was extracted using
274 RNeasy Plus Mini Kit from Qiagen which includes gDNA eliminator columns, following the
275 manufacturer's protocol. Quality of RNA was verified, and subsequent RNA sequencing was
276 carried out by Farncombe Metagenomic Facility at McMaster University. RNA integrity was
277 checked using the Agilent bioanalyzer. mRNA was converted to cDNA after enrichment. cDNA
278 libraries were sequenced using an Illumina HiSeq machine (1x50 bp sequence reads). Data were
279 analyzed as previously described ⁶. Before the analysis of differentially expressed genes (DEGs),
280 reads were filtered by quality and counted. Genes, showing low levels of expression were removed
281 using EdgeR package in R. Statistical analysis was performed with 11,848 genes. The Limma
282 package in R was used to identify DEGs in stimulated macrophages and DEGs were then compared
283 to their respective unstimulated controls. Stringent criteria, including Log₂ of fold-change ≥1.5 or
284 ≤-1.5, and corrected p value <0.05 were applied to filter DEGs. Ontology analysis for the Biological
285 Processes component was performed using BINGO plugin, and barcharts were created using top
286 10 biological processes shared between the comparisons (reflecting adjusted p-values averaged
287 between the pairwise comparisons) or using all biological processes unique to the comparison of
288 interest.

289 Outcomes

290 The primary outcome of this trial was safety of a single administration of vaccine delivered
291 to the respiratory tract by aerosol or intramuscular injection. The frequency and severity of
292 vaccine-related local and systemic adverse events were collected from participants from a self-
293 completed diary for 14 days after vaccination (fever, chills, cough, wheezing, sneezing, shortness

294 of breath, chest pain, headache, fatigue or malaise, conjunctivitis, rhinitis, epistaxis, injection site
295 reaction, syncope or light-headedness) and at scheduled follow-up visits.

296 Routine laboratory biochemical and haematological tests (CBC, sodium, potassium,
297 creatinine, AST, bilirubin) were measured at 2, 4 and 12 weeks after vaccination and lung function
298 (FEV1 and FVC) were measured at 2, 4, 8 and 12 weeks after vaccination. The secondary outcome
299 was comparison of immunogenicity among the different routes and aerosol dose groups.

300 Statistical analysis

301 Adverse events were reported descriptively. Immunogenicity data were analyzed using
302 Prism (version 9.2.0). Data are expressed as the mean value (horizontal line) with 95% confidence
303 interval. Box plots show mean value (horizontal line) with 95% confidence interval (whiskers) and
304 boxes extend from the 25th to 75th percentiles. Violin plots show the median and quartiles. Pie chart
305 shows median proportions of polyfunctional Ag-specific T cells. Wilcoxon matched pairs signed
306 rank test was used when comparing change of T cell or cytokine responses at various timepoints
307 from the baseline values within the same vaccination group (LD aerosol, HD aerosol and IM
308 groups) Mann-Whitney U test was used for comparison of the difference in T cell responses
309 between vaccination groups. For correlation analysis, the Spearman rank coefficient test was
310 used. Two-tailed p values of less than 0.05 were considered significant.

311

312 **Results**

313 During the period of March 2019 to February 2021, we enrolled 36 BCG-vaccinated
314 healthy adults between 18 and 55 years of age at McMaster University Medical Centre, Hamilton,
315 Ontario, Canada. 4 participants were excluded (two withdrew consent and two were withdrawn
316 before vaccination because they were unable to comply with the study visit requirements) and one
317 did not complete any follow-up visits after vaccination because of COVID restrictions. 31
318 participants completed the study, 11 in the low dose aerosol group, 11 in the high dose aerosol
319 group and 9 in the intramuscular group (Fig 1). The demographic and baseline characteristics of
320 the study participants were similar among study groups (Table 1).

321

322 ***Characterization of inhaled aerosol delivery method and aerosol droplets using Aeroneb® Solo***
323 ***device***

324 The Aeroneb® Solo Micropump was selected to be part of the device set up for aerosol
325 generation and delivery in our study (Fig S1). A fill volume of 0.5 ml in the nebulizer was
326 determined to be optimal for vaccine delivery in saline. Subjects completed inhalation of this
327 volume containing the vaccine via tidal breathing in approximately 2.5 minutes (Table 2). The
328 emitted dose of vaccine available at the mouth was found to be approximately 50% of the loaded
329 dose in the nebulizer (Table 2). The majority of aerosol droplets were <5.39 µm (85%) or between
330 2.08 and 5.39 µm in diameter conducive to vaccine deposition in major airways. Thus, the amount
331 of aerosol available at the mouth and subsequently deposited in the lung was 42.5%¹⁷. The
332 estimated rate of viable vaccine from aerosol droplets generated by the nebulizer was 17.4%. The
333 dose loaded in the nebulizer for aerosol inhalation was thus corrected according to the estimated
334 losses of vaccine within the device.

335 ***Safety of inhaled aerosol and intramuscular injected AdHu5-Ag85A vaccine***

336 Both low and high doses of AdHu5Ag85A administered by aerosol inhalation or the
337 intramuscular injection were safe and well-tolerated. Respiratory adverse events were infrequent,
338 mild, transient and similar among groups (Table 3). Intramuscular injection was associated with a
339 mild local injection site reaction in two participants. Systemic adverse events were also infrequent,
340 mild, transient and similar among groups (Table 3). One participant who received low dose aerosol
341 vaccine developed genital lesions consistent with primary HSV-1 infection the day following the
342 week 2 bronchoscopy, which resolved without complication with oral valacyclovir, and one
343 participant developed plantar fasciitis on day 13 following vaccination which was attributed to
344 mechanical strain and resolved with acetaminophen. There were no grade 3 or 4 adverse events
345 reported nor any serious adverse events.

346 There were no clinically significant abnormalities of laboratory tests at weeks 2, 4 and 12
347 following vaccination. Follow-up respiratory functional determinations FEV1 and FVC were
348 similar to baseline values in all participants across all three groups (Fig S2-A/B).

349 Bronchoscopy and bronchoalveolar lavage were generally well tolerated in all participants.
350 As expected, in some participants the procedures were associated with mild cough, sore throat,
351 low-grade fever, headache and a transient drop in FEV1. The appearance of the bronchial mucosa

352 was judged as normal in all participants at each time point. Adequate bronchoalveolar lavage fluid
353 (BALF) volumes were obtained following bronchoalveolar lavage and on average 10-20 million
354 total cells were obtained.

355 *Aerosol AdHu5Ag85A vaccination induces robust and sustainable Th1 responses in the airway*

356 Bronchoalveolar lavage was obtained successfully from all participants with a median
357 return volume of 87.5 ml (IQR: 72.5-98) from a total of 160 ml saline instilled and a median total
358 cell number of 0.14 million/ml BALF (IQR: 0.1-0.2). Cellularity in the airway significantly
359 increased 2wk after both low dose (LD) and high dose (HD) aerosol vaccination and in LD aerosol
360 group, cellularity remained significantly heightened up to 8wk post-vaccination compared with
361 baseline (Fig S2-C). Both LD and HD aerosol vaccination led to a transient reduction in airway
362 macrophages, but the lymphocyte counts significantly increased only in LD cohort (Fig S2-D/E).
363 Importantly, both neutrophils and epithelial cells in the airway remained either absent or unaltered
364 following aerosol vaccination (Fig S2-D/E), indicating no significant airway inflammation. In
365 comparison, there were no marked changes in total cellularity and any leukocyte subsets in the
366 airway after intramuscular (IM) vaccination (Fig S2-C/F).

367 Evaluation of Th1 responses in the airways (BALF) cells by intracellular cytokine
368 immunostaining showed that both LD and HD aerosol AdHu5Ag85A markedly increased Ag85A
369 peptide pool (Ag85A p. pool)-specific or reactive, IFN γ -, TNF α - and/or IL-2-producing CD4 T
370 cells in the airways at 2wk after vaccination compared with the respective baseline responses (Fig
371 2A/B/C). On average, the total Ag-specific cytokine-producing CD4 T cells represented ~25% of
372 all CD4 T cells at 2wk post-LD or HD aerosol and they remained significantly elevated up to 8wk
373 in the airways of LD cohort (Fig 2A/B). In contrast, IM AdHu5Ag85A vaccination failed to induce
374 Ag-specific CD4 T cells in the airways (Fig 2A). Compared with CD4 T cells, although the levels
375 of airway CD8 T cell responses were much smaller, they were significantly increased at both 2
376 and 8wk, particularly following LD aerosol vaccination (Fig 2D). Of interest, there was also a
377 small but increased number of CD8 T cells at 2wk after IM vaccination.

378 Analysis of polyfunctionality of vaccine-activated CD4 and CD8 T cells reactive to Ag85A
379 in the airways revealed that LD aerosol vaccination led to induction of higher magnitude of CD4
380 T cells that co-expressed IFN γ , TNF α and IL-2 (3+) and any of two cytokines (2+) than those
381 producing single cytokine (1+) (Fig 2E/F). Importantly, polyfunctional CD4 T cells remained

382 significantly increased over the baseline up to 8wks. Similarly, LD aerosol vaccination also
383 significantly increased the polyfunctional CD8 T cells, particularly at 8wks, in the airways, though
384 at much lower overall magnitude compared to CD4 T cells (Fig 2F). In comparison, HD aerosol
385 vaccination led to significantly increased polyfunctional CD4 but not CD8 T cells reactive to
386 Ag85A (Fig S3-A/B).

387 Given that the LD aerosol AdHu5Ag85A was consistently highly immunogenic, we
388 profiled the polyfunctional CD4 and CD8 T cells in the airways of LD cohort in greater detail.
389 While at 2wk, a greater proportion of Ag85A-reactive CD4 T cells were polyfunctional
390 (IFN γ +TNF α +IL-2+, IFN γ +TNF α + or IFN γ +IL-2+) with some of them also being single cytokine
391 producers, at 8wk the vast majority of them (>95%) became polyfunctional (Fig 2G). In
392 comparison, most of the CD8 T cells at 2wk were single cytokine producers (TNF α +) but at 8wk
393 the majority of them turned to be polyfunctional, mostly being IFN γ +TNF α + (Fig 2G).

394 Since the trial participants were previously BCG-vaccinated, we examined the overall T
395 cell reactivity to stimulation with multi-mycobacterial antigens. We found considerable CD4 T
396 cells present in the airways to be reactive to a cocktail of mycobacterial antigens even prior to
397 vaccination and they remained unaltered after LD, HD or IM vaccination (Fig S3-C). These BCG-
398 specific CD4 T cells in the airways of LD group were mostly polyfunctional (Fig S3-D/E).
399 Similarly, small numbers of pre-existing BCG-specific CD8 T cells in the airways were not altered
400 by aerosol or IM vaccination (Fig S3-F).

401 The above data suggest that inhaled aerosol, but not intramuscular, AdHu5Ag85A
402 vaccination can induce robust antigen-specific T cell responses within the respiratory tract.
403 Furthermore, a low-dose (1×10^6 PFU) aerosol vaccination is superior to a high dose (2×10^6 PFU)
404 aerosol in inducing robust and sustainable respiratory mucosal immunity. The mucosal responses
405 induced by AdHu5Ag85A vaccine are predominantly polyfunctional CD4 T cells in nature with
406 some levels of polyfunctional CD8 T cells. The pre-existing CD4 T cells of multi-mycobacterial
407 antigen specificities in the airway of BCG-vaccinated trial participants were not significantly
408 impacted by AdHu5Ag85A aerosol vaccination.

409 ***Aerosol vaccination induces airway-resident memory T cells (T_{RM}) expressing the lung homing***
410 ***molecule $\alpha 4\beta 1$ integrin***

411 Lung tissue-resident memory T cells are critical to protective mucosal immunity¹⁹. Hence,
412 we next determined whether antigen-specific T cells induced by aerosol AdHu5Ag85A
413 vaccination were of tissue-resident memory phenotype and compared them to those by IM
414 vaccination. BALF cells obtained before and at select timepoints post-vaccination were stimulated
415 with Ag85A p. pool and immunostained for co-expression of two key T_{RM} surface markers CD69
416 and CD103 by antigen-specific IFN γ -producing CD4 or CD8 T cells (Fig 3A). Marked increases
417 in Ag85A-specific IFN- γ ⁺ CD4 and CD8 T cells co-expressing CD69 and CD103 were seen only
418 in the airway of LD and HD aerosol vaccine groups, but not in IM group (Fig 3B/C). Although
419 T_{RM} increases at 8wk post-aerosol vaccination compared to the baseline were only marginally
420 statistically significant (95% CI) probably due to small sample sizes, remarkable proportions of
421 Ag85A-specific CD4 T cells (~20%) and CD8 T cells (~54%) present in the airways of aerosol
422 vaccine groups were T_{RM} (Fig 3D). As expected, there was no detectable antigen-specific T_{RM} in
423 the peripheral blood before and after vaccination.

424 We also studied T cell surface expression of $\alpha 4\beta 1$ integrin (VLA-4; or CD49d for $\alpha 4$), known
425 to be expressed on memory CD4 T cells in human airways²⁰. Since CD49d may be involved in the
426 homing of circulating T cells to the airway, we first examined CD49d expression on Ag85A-specific
427 CD4 T cells in the circulation. There were small but significantly increased frequencies of circulating
428 CD49d-expressing IFN γ ⁺CD4 T cells, particularly at 2wk following LD or HD aerosol vaccination
429 (Fig 3E). In comparison, there were much greater frequencies of CD49d-expressing IFN γ ⁺CD4 T cells
430 (out of total CD4 T cells) in the airways induced by aerosol vaccination (Fig 3F), compared to their
431 frequencies in the circulation (Fig 3E) and in contrast with the lack of such T cells in the airways of
432 IM group (Fig 3G). In fact, the majority of Ag85A-specific CD4 T cells in the airways of LD and
433 HD groups expressed CD49d (57% and 74%, respectively). The data together indicate that aerosol
434 AdHu5Ag85A vaccination, but not IM route of vaccination, is uniquely capable of inducing
435 antigen-specific T cells in the airways endowed with respiratory mucosal homing and T_{RM}
436 properties.

437 Since besides mucosal adaptive immunity, respiratory delivery of AdHu5Ag85A vaccine
438 in experimental animals induced a trained phenotype in airway macrophages^{6,21}, we examined
439 whether aerosol vaccination could also alter the immune property of human alveolar macrophages
440 (AM). To this end, we elected to examine the transcriptomics of BALF cells obtained from 5
441 participants before (wk0) and after (wk8) LD aerosol vaccination. Before RNA isolation, the cells,

442 upon revival from frozen stock, were enriched for AM and cultured with or without stimulation
443 with *M.tb* lysates and transcriptionally profiled by RNAseq analysis. Principal component analysis
444 (PCA) revealed that unstimulated (US) and stimulated (S) AM populations were separated away
445 from each other (Fig S4-A). We then identified the differentially expressed genes (DEGs) by
446 comparing wk0- and wk8-stimulated AM with respective unstimulated AM. A total of 2,726 genes
447 were differentially expressed upon stimulation in pairwise analysis of which 1667 genes (61%)
448 were shared between the baseline (wk0) Group 3/1 and aerosol vaccine (wk8) Group 4/2 (Fig S4-
449 B). As expected, the shared genes were significantly enriched in biological processes associated
450 with immune response and regulation of cell death (Fig S4-C). Further by pairwise analysis, we
451 identified 194 and 426 genes uniquely upregulated and downregulated, respectively, in stimulated
452 aerosol (Group 4) AM (Fig S4-D). The uniquely up-regulated genes in stimulated wk8 aerosol AM
453 showed enrichment in a number of biological processes including response to anoxia (OXTR,
454 CTGF), inflammatory response to antigenic stimuli (IL2RA, IL1B, IL20RB), tyrosine
455 phosphorylation of STAT protein (IFNG, F2R, OSM), regulation of IL-10 production (CD83,
456 IRF4, IL20RB, IDO1), response to IL-1 (RIPK2, SRC, IRAK2, IL1R1, XYLT1, RELA) and
457 histone demethylation (KDM6B, KDM5B, KDM1A, KDM7A, JMJD6) (Fig S4-E). In comparison,
458 the uniquely down-regulated genes in wk8 aerosol AM did not appear significantly enriched for
459 any biological processes. These data suggest that LD aerosol vaccination leads to persisting
460 transcriptional changes in airway-resident alveolar macrophages poised for defense responses.

461 *Aerosol vaccination induces levels of systemic Th1 responses comparable to intramuscular* 462 *vaccination*

463 Assessment of overall antigen-specific reactivity of T cells in the circulation before and
464 after vaccination by using whole blood samples incubated with Ag85A peptides indicated that both
465 aerosol, particularly LD aerosol, and IM AdHu5Ag85A vaccination induced significant systemic
466 immune responses as shown by raised IFN γ , TNF α and IL-2 levels in plasma (Fig 4A/B/C). Area
467 under curve (AUC) analysis, which reflects the overall magnitude of responses, did not differ
468 between LD aerosol and IM groups in cytokine production in response to Ag85A p. pool
469 stimulation (IFN γ p=0.0910; TNF α p=0.6207; IL-2 p=0.8703). However, IM vaccine-induced
470 systemic T cell responses appeared to remain significantly increased over a longer duration (Fig
471 4C). In comparison, HD aerosol group had significantly lower IFN γ production than IM group

472 (AUC compared to IM- $p=0.0117$) whereas they did not differ from each other in the production
473 of TNF α and IL-2 (Fig 4B/C).

474 Further examination of relative activation of CD4 and CD8 T cells by aerosol and IM
475 vaccinations using intracellular cytokine staining revealed that compared to the respective baseline,
476 aerosol vaccination activated the circulating Ag85A-specific CD4 T cells to significant levels
477 while IM vaccination moderately increased such responses (Fig 4D). However, the overall
478 magnitude of responses did not differ significantly between aerosol and IM groups (AUC: LD
479 aerosol- $p=0.1961$; HD aerosol- $p=0.3545$ compared to IM). Both LD/HD aerosol and IM
480 vaccination also significantly increased Ag85A-specific polyfunctional CD4 T cells co-expressing
481 three (3+) or any two (2+) cytokines in the circulation (Fig 4E). Consistent with the airway Ag85A-
482 specific CD4 T cell responses (Fig 2A/B/C) in both LD and HD aerosol groups, circulating
483 polyfunctional CD4 T cells also generally peaked at 2wk post-vaccination and remained
484 significantly increased up to 8wk (Fig 4E). In comparison, 3+ polyfunctional CD4 T cells in IM
485 group significantly increased at 4wk and remained increased up to 8wk (Fig 4E). The overall
486 magnitude of circulating 3+ polyfunctional CD4 T cells in IM group was however significantly
487 higher than those in aerosol groups (AUC: LD aerosol, $p=0.0144$ and HD aerosol, $p=0.0393$
488 compared to IM). Circulating 2+ polyfunctional CD4 T cells did not differ significantly between
489 these groups (AUC not significantly different). Consistent with our previous observation⁸, besides
490 its activating effects on circulating CD4 T cells, IM vaccination also significantly increased
491 Ag85A-specific CD8 T cells up to 16wk (Fig 4F). By comparison, aerosol vaccination minimally
492 induced such CD8 T cells in the circulation (Fig 4F). Compared to circulating CD4 T cells, similar
493 to the overall kinetics of total cytokine+ CD8 T cells (Fig 4F), circulating Ag85A-specific
494 polyfunctional CD8 T cells peaked behind the peak CD4 T cell responses in all vaccine groups
495 (Fig 4G).

496 The kinetics of polyfunctional profiles of circulating CD4 T cells were further examined
497 in greater detail with a focus on LD aerosol vaccine group and its comparison with IM group.
498 There existed considerable differences in the polyfunctional profile of circulating Ag85A-specific
499 CD4 T cells between LD aerosol and IM groups (Fig S5-A). In LD aerosol group, the proportion
500 of IFN γ +TNF α +IL-2+ progressively shrank and at 16wk, ~75% of the population were TNF α +IL-
501 2+ and IFN γ +TNF- α + together with single TNF α + CD4 T cells. In comparison, in IM group the

502 proportion of IFN γ +TNF α +IL-2+ progressively expanded, constituting ~ 75% of the population
503 at 16wk (Fig S5-A).

504 Upon examination of circulating BCG-specific CD4 T cells (reactive to *M.tb*CF+rAg85A
505 stimulation), we found that they were not strikingly increased in aerosol and IM vaccine groups
506 although the trend was higher in IM group (Fig S5-B/C) and AUC values did not differ
507 significantly between aerosol and intramuscular groups (LD aerosol, p=0.0870; HD aerosol,
508 p=0.2666 compared to IM). However, LD and HD aerosol vaccination had a significant enhancing
509 effect on the polyfunctionality of pre-existing circulating BCG-specific CD4 T cells (Fig S5-C).
510 Similar to BCG-specific circulating CD4 T cells (Fig S5-B), BCG-specific circulating CD8 T cells
511 were not significantly increased by either aerosol or IM vaccination (Fig S5-D).

512 These data together indicate that besides markedly induced mucosal T cell immunity (Fig
513 2/3), respiratory mucosal vaccination via inhaled aerosol, particularly LD aerosol, can also induce
514 systemic polyfunctional CD4 T cell responses at levels comparable to those by IM route of
515 vaccination in previously BCG-vaccinated humans.

516 *Pre-existing anti-AdHu5 antibodies have minimal effects on the immunogenicity of aerosol* 517 *AdHu5Ag85A vaccination*

518 The high prevalence of circulating pre-existing antibodies (Ab) against AdHu5 in human
519 populations may negatively impact on the potency of AdHu5-vectored vaccines following
520 intramuscular administration²². However, little is known about its effect on the potency of
521 respiratory mucosal-delivered AdHu5-vectored vaccine. To address this question, we first
522 examined the levels of AdHu5-specific total immunoglobulin G (IgG) in the circulation and
523 airways (BALF) before and after vaccination (wk 0 vs 4 in circulation; wk 0 vs. 8 in BALF). In
524 keeping with our previous findings⁸, there were significant levels of pre-existing circulating
525 AdHu5-specific total IgG in most of the trial participants (10^4 - 10^5), and the levels were comparable
526 between the groups (using Kruskal-Wallis test p=0.2048) (Table 4). These titres significantly
527 increased after HD aerosol or IM AdHu5Ag85A vaccination but not after LD aerosol vaccination.
528 In comparison, pre-existing levels of anti-AdHu5 total IgG in the airways were 1-1.5 log less than
529 the levels in the circulation and were comparable between groups (using Kruskal-Wallis test
530 p=0.2048). Of interest, LD and HD aerosol as well as IM vaccination did not alter the pre-existing

531 anti-AdHu5 total IgG levels in the airways (Table 4) but the data from HD aerosol and IM groups
532 should be interpreted with caution due to the small sample size at 8wk.

533 Because the total anti-AdHu5 Ab titres may not always correlate with AdHu5-neutralizing
534 capacity in the circulation ⁸, we further assessed the AdHu5-neutralizing Ab (nAb) titres before
535 and after vaccination in the circulation and airways by using a bioassay. The pre-existing AdHu5-
536 nAb titres in the circulation were comparable between groups (using Kruskal-Wallis test p=0.3588)
537 with 27%, 54% and 66% of participants in LD, HD and IM groups having >10² AdHu5-nAb titres,
538 respectively. Of interest, while IM vaccination with AdHu5Ag85A significantly increased the
539 circulating AdHu5-nAb titers by an average of 1.5 logs, LD or HD aerosol vaccination had no such
540 effect (Table 4). On the other hand, similar to total anti-AdHu5 IgG levels, pre-existing AdHu5-
541 nAb titers in the airways were ~1 log less than those in the circulation (Table 4). Of importance,
542 63%, 36% and 33% of participants in LD, HD and IM groups, respectively, had no detectable
543 baseline AdHu5-nAb titers in their airways which remained unaltered following vaccination
544 (Table 4). We further found a significant positive correlation between AdHu5-nAb and total
545 AdHu5 IgG titres both in the circulation and airways (Fig S6-A/B).

546 Given that many of the trial participants had moderate to significant levels of AdHu5-nAb
547 titers in the circulation and ~50% of them also had a small but detectable level of pre-existing
548 AdHu5-nAb titres in the airways, we next examined whether such nAbs present in the airways and
549 blood may have negatively impacted the immunopotency of LD aerosol and IM vaccination,
550 respectively. To this end, % airways or blood total cytokine+ Ag85A-specific CD4 T cells at the
551 peak response time (2 weeks post-vaccination) for individual participants was plotted against
552 corresponding pre-existing AdHu5-nAb titre and Spearman rank correlation test was performed.
553 There was no significant correlation between pre-existing airways AdHu5-nAb titers and the
554 magnitude of vaccine-induced CD4 (Fig S6-C) and CD8 (Fig S6-D) T cell responses in the airways
555 following LD aerosol vaccination. Of note, one participant who hardly responded to aerosol
556 vaccine did have the highest neutralization titers in the cohort (Fig S6-C). On the other hand,
557 consistent with our previous observation ⁸, there was no significant correlation between pre-
558 existing circulating AdHu5-nAb titers and the magnitude of antigen-specific CD4 (Fig S6-E) and
559 CD8 (Fig S6-F) T cell responses in the blood following IM vaccination. The above data together
560 suggest that while there is high prevalence of pre-existing circulating anti-AdHu5 nAb in humans

561 enrolled in our study, most of trial participants have either undetectable or very low levels of pre-
562 existing anti-AdHu5 nAb titers in the airways. IM AdHu5Ag85A vaccination increases AdHu5
563 nAb titers in the circulation whereas aerosol vaccination does not do so either in the airways or in
564 the circulation. Furthermore, overall, the presence of AdHu5 nAb does not seem to have a
565 significant impact on vaccine immunogenicity.

566 **Discussion**

567 This represents the first clinical study to have fully characterized the method to deliver
568 aerosolized adenoviral-vectored vaccine to human lungs and to demonstrate its superiority in
569 inducing respiratory mucosal immunity over the intramuscular injection.

570 Both low and high aerosol doses of AdHu5Ag85A were safe and well-tolerated.
571 Respiratory adverse events were rare, mild, transient and similar among groups and the respiratory
572 function determined by FEV1 and FVC were within normal limits. Systemic adverse events were
573 also similarly rare, mild and transient. There were no grade 3 or 4 adverse events reported nor any
574 serious adverse events. There were no clinically significant abnormalities of routine laboratory
575 tests at weeks 2, 4 and 12 following either aerosol or IM vaccination.

576 Our finding that respiratory mucosal vaccination via inhaled aerosol delivery, but not the
577 parenteral intramuscular vaccination, is capable of induction of robust respiratory mucosal
578 immunity in human lungs is consistent with the well-established knowledge from animal models
579 of TB and other respiratory infections^{3,23-25}. While both the low and high aerosol doses were found
580 to be safe, our findings support the low-dose aerosol, rather than the high-dose, to be optimal as it
581 led to more consistently increased T cell responses in the airway. Of note, this low aerosol dose
582 (10^6 PFU) was 100 times smaller than the IM dose (10^8 PFU) in our study. The remarkable
583 immunogenicity of a rather small dose of a human serotype 5 Ad (AdHu5)-vectored vaccine at
584 human respiratory mucosa was observed despite the common knowledge that the majority of
585 humans have varying degrees of pre-existing antibodies against AdHu5^{22,26}. The superiority of
586 AdHu5-vectored vaccine delivered via aerosol, as opposed to IM injection, in inducing respiratory
587 mucosal immunity, suggests the respiratory tract to be an immune privileged site in terms of anti-
588 AdHu5 nAb. Indeed, we find that ~50% of our trial participants have no detectable pre-existing
589 nAb titers and the rest of them have rather low pre-existing nAb titers in the airways, contrasting

590 to readily measurable pre-existing nAb titers in the blood of most of the trial participants. Such
591 compartmentalized prevalence of anti-AdHu5 Ab in the circulation, but not in the airways of
592 humans, is also reported in a previous study ²⁷. Consideration of the relative prevalence of anti-
593 human Ad nAb is important to the design of human Ad-based vaccine strategies ^{15,22,28}. In this
594 regard, although probably due to relatively small sample size, we did not find a significant negative
595 correlation between AdHu5 nAb titers and T cell responses in the peripheral blood following IM
596 injection of AdHu5Ag85A vaccine, a strong negative correlation has been seen in larger clinical
597 trials with AdHu5-based vaccines ^{14,29}. Also, for the first time, we find that aerosol delivery of an
598 AdHu5-vectored vaccine did not enhance AdHu5 nAb in the airways whereas the IM route of
599 vaccination significantly enhanced nAb titers in the blood. This represents an additional advantage
600 of inhaled aerosol delivery of Ad-vectored vaccine, suggesting the feasibility of repeated aerosol
601 deliveries of such vaccines for undiminished immunopotency. Thus, our findings together suggest
602 that besides its unique strength and advantage in inducing much desired respiratory mucosal
603 immunity and repeatability, the inhaled aerosol Ad-based vaccine strategy is pain/needle-free and
604 requires only a small dose to be effective, helping with global vaccine distribution when vaccine
605 supplies may be limited.

606 Pulmonary TB has remained a major global health issue. Despite great strides made in the
607 past couple of decades to develop improved TB vaccine strategies, BCG, a century-old TB vaccine,
608 still continues to be used worldwide ³⁰. To effectively control the global TB epidemic, new,
609 unconventional vaccine approaches such as respiratory mucosal vaccine strategies are likely
610 required ^{2,3,5,24}. Respiratory mucosal immunization strategies with appropriately chosen vaccine
611 platforms are adept at inducing the all-round protective immunity consisting of humoral immunity,
612 tissue-resident memory T cells, and trained innate immunity ³. The scientists at Jenner Institute of
613 Oxford University pioneered an inhaled aerosol method to deliver an MVA-vectored TB vaccine
614 to human respiratory tract and found much improved T cell responses in the airways over that by
615 intradermal injection ^{10,12}. Of note, a different aerosol device was used, and the aerosol particles
616 and delivery efficiency were not characterized in these studies. Furthermore, since in these studies,
617 bronchoscopy was performed only once to assess the local mucosal immune responses at 1 week
618 post-vaccination, it is unclear whether aerosol vaccine-activated effector T cells may persist,
619 becoming long-term memory T cells in the airways. In comparison, in our current study, not only
620 were the aerosol droplets and delivery efficiency fully characterized, but bronchoscopy was

621 performed before vaccination and twice at 2 and 8 weeks post-vaccination. Since, as shown in our
622 current study and by others ³¹, the airways of previously BCG-vaccinated or PPD-positive humans
623 harbor mycobacterial antigen-specific T cells at baseline, we believe that bronchoscopy carried
624 out before and after vaccination is needed to help differentiate the authenticity of vaccine-induced
625 T cell responses. Based on immune analysis of the cells harvested via 8-week post-aerosol
626 bronchoscopy, our study for the first time offers the critical evidence that inhaled aerosol viral-
627 vectored vaccine can induce persisting tissue-resident memory T cells within human respiratory
628 tract. Using RNAseq, our study also reveals the lasting transcriptional changes in airway
629 macrophages, indicative of trained innate immunity, following aerosol vaccination. We have
630 recently reported that in preclinical models, respiratory mucosal-delivered AdHu5-vectored TB
631 vaccine induces lasting memory airway macrophages capable of trained innate immunity against
632 *M.tb* and unrelated bacterial pathogens ^{6,21}. Incorporating the ability of a vaccine vector to induce
633 tissue-resident trained innate immunity alongside tissue-resident adaptive immunity into the
634 design of TB vaccine strategies may provide the best possible protection ^{3,5}.

635 The well-characterized inhaled aerosol vaccine technology and its superiority to induce
636 respiratory mucosal immunity demonstrated in our current study also offers a foundation and the
637 important proof of concept for developing the next-generation COVID-19 vaccine strategies.
638 Indeed, the effective global control of COVID-19 via the roll-out of the first-generation vaccines
639 has met with threats from emerging variants of concern, dwindling vaccine-induced immunity,
640 and increasing break-through infections ¹⁶. Of note, several approved first-generation COVID-19
641 vaccines are adenoviral-vectored but they are all administered via intramuscular injection ¹⁵.
642 Although a recent study has shown that it is safe and well-tolerated to deliver via inhaled aerosol
643 an AdHu5-vectored COVID-19 vaccine into human respiratory tract ¹⁴, there are a number of
644 critical drawbacks associated with this study. This study did not evaluate the local respiratory
645 mucosal immune responses following aerosol and intramuscular vaccination and it is unclear that
646 how much aerosolized biologically active vaccine was deposited into human respiratory tract.
647 Furthermore, in this study, 2-repeated high aerosol doses (up to 2×10^{10} vp/dose) were compared
648 with an IM prime -aerosol boost regimen, leaving the question open whether 2-repeated aerosol
649 doses are scientifically justified or is it counterproductive. As we have shown in our current study,
650 the respiratory tract is an immunologically highly conducive site for adenoviral-vectored
651 immunization and a rather small single aerosol dose ($\sim 3 \times 10^7$ vp) is able to induce high frequencies

652 of antigen-specific tissue-resident memory T cells in the airways. We further show that a relatively
653 small increase in aerosol dose did not translate to greater T cell responses, but rather, it caused
654 inconsistent immune responses probably due to immune overactivation.

655 In conclusion, our current study has provided technological details for safely and efficiently
656 delivering aerosolized adenoviral-vector vaccine into human respiratory tract and demonstrated its
657 superiority to induce respiratory mucosal immunity over parenteral intramuscular injection. Our
658 findings will foster the development of effective vaccine strategies against not only TB but also
659 other respiratory infections including COVID-19.

660

661 **Contributors**

662

663 FS, ZX, GMG, MJ designed the trial. MBD, MCM, MRT, ZX, FS characterized the aerosol device
664 and aerosol droplets. BDL, MCM took charge of vaccine GMP manufacturing. MJ, DKF, SA, AZ,
665 AD performed immunological assays and data analysis. EA, KJH, RFS, RC, PMO, MK, IS, GMG,
666 FS contributed to participant recruitment, clinical data management, safety assessment,
667 bronchoscopy or other clinical assistance. ZX, FS secured the funding. MJ, ZX, FS wrote the
668 manuscript.

669

670 **Declaration of interests**

671 MBD, ZX and FS are co-inventors on a provisional patent on inhaled aerosol delivery of Ad-
672 vectored vaccines. All other authors declare no competing interests.

673 **Acknowledgements**

674 The work is supported by funds from the Canadian Institutes of Health Research (CIHR) Project
675 & Foundation Programs and the Collaborative Health Research Program of CIHR and the Natural
676 Sciences and Engineering Research Council of Canada. The authors are grateful to Tracy Tazeeo,
677 Xueya Feng and Natallia Kazhdan for their technical assistance, and to all of the trial volunteers.

678

679

680 **References**

- 681 1 WHO. WHO | Global tuberculosis report 2019. 2020 DOI:.1037//0033-2909.I26.1.78.
- 682 2 Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of
683 tuberculosis vaccine development. *Lancet Infect Dis* 2020; **20**: e28–37.
- 684 3 Jeyanathan M, Yao Y, Afkhami S, Smaill F, Xing Z. New Tuberculosis Vaccine
685 Strategies: Taking Aim at Un-Natural Immunity. *Trends Immunol* 2018; **39**: 419–33.
- 686 4 Jeyanathan M, Shao Z, Yu X, *et al.* AdHu5Ag85A respiratory mucosal boost
687 immunization enhances protection against pulmonary tuberculosis in bcg-primed non-
688 human primates. *PLoS One* 2015; **10**: e0135009.
- 689 5 Xing Z, Afkhami S, Bavananthasivam J, *et al.* Innate immune memory of tissue-resident
690 macrophages and trained innate immunity: Re-vamping vaccine concept and strategies. *J*
691 *Leukoc Biol* 2020; **108**: 825–34.
- 692 6 Yao Y, Jeyanathan M, Haddadi S, *et al.* Induction of Autonomous Memory Alveolar
693 Macrophages Requires T Cell Help and Is Critical to Trained Immunity. *Cell* 2018; **175**:
694 1634-1650.e17.
- 695 7 Netea MG, Domínguez-Andrés J, Barreiro LB, *et al.* Defining trained immunity and its
696 role in health and disease. *Nat Rev Immunol* 2020; **20**: 375–88.
- 697 8 Smaill F, Jeyanathan M, Smieja M, *et al.* A Human Type 5 Adenovirus-Based
698 Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting
699 Anti-Adenovirus Immunity. *Sci Transl Med* 2013; **5**: 205ra134-205ra134.
- 700 9 Jeyanathan M, Damjanovic D, Yao Y, Bramson J, Smaill F, Xing Z. Induction of an
701 immune-protective t-cell repertoire with diverse genetic coverage by a novel viral-
702 vectored tuberculosis vaccine in humans. *J Infect Dis* 2016; **214**: 1996–2005.
- 703 10 Satti I, Meyer J, Harris SA, *et al.* Safety and immunogenicity of a candidate tuberculosis
704 vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1,
705 double-blind, randomised controlled trial. *Lancet Infect Dis* 2014; **14**: 939–46.
- 706 11 Dilraj A, Cutts FT, de Castro JF, *et al.* Response to different measles vaccine strains given

- 707 by aerosol and subcutaneous routes to schoolchildren: a randomised trial. *Lancet*
708 (*London, England*) 2000; **355**: 798–803.
- 709 12 Manjaly Thomas Z-R, Satti I, Marshall JL, *et al.* Alternate aerosol and systemic
710 immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I
711 randomised controlled trial. *PLoS Med* 2019; **16**: e1002790.
- 712 13 Low N, Bavdekar A, Jeyaseelan L, *et al.* A randomized, controlled trial of an aerosolized
713 vaccine against measles. *N Engl J Med* 2015; **372**: 1519–29.
- 714 14 Wu S, Huang J, Zhang Z, *et al.* Safety, tolerability, and immunogenicity of an aerosolised
715 adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary
716 report of an open-label and randomised phase 1 clinical trial. *Lancet Infect Dis* 2021;
717 published online July. DOI:10.1016/S1473-3099(21)00396-0.
- 718 15 Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological
719 considerations for COVID-19 vaccine strategies. *Nat Rev Immunol* 2020; **20**: 615–32.
- 720 16 Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19
721 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.
722 *Nat Rev Immunol* 2021; : DOI: 10.1038/s41577-021-00592-1
- 723 17 Dolovich M, Tazzeo T, Xing Z, *et al.* In Vitro Evaluation Of The Aerogen Micropump
724 Aerosol Delivery System For Delivering Adhu5ag85a Tb Vaccine To Human Subjects.
725 *Am J Respir Crit Care Med* 2015; **191**.
- 726 18 Morgan BA, Manser M, Jeyanathan M, Xing Z, Cranston ED, Thompson MR. Effect of
727 Shear Stresses on Adenovirus Activity and Aggregation during Atomization To Produce
728 Thermally Stable Vaccines by Spray Drying. *ACS Biomater Sci Eng* 2020; **6**: 4304–13.
- 729 19 Szabo PA, Miron M, Farber DL. Location, location, location: Tissue resident memory T
730 cells in mice and humans. *Sci Immunol* 2019; **4**: eaas9673.
- 731 20 Walrath JR, Silver RF. The $\alpha 4\beta 1$ integrin in localization of Mycobacterium tuberculosis-
732 specific T helper type 1 cells to the human lung. *Am J Respir Cell Mol Biol* 2011; **45**: 24–
733 30.

- 734 21 D'Agostino MR, Lai R, Afkhami S, *et al.* Airway Macrophages Mediate Mucosal
735 Vaccine-Induced Trained Innate Immunity against *Mycobacterium tuberculosis* in Early
736 Stages of Infection. *J Immunol* 2020; **205**: 2750–62.
- 737 22 Afkhami S, Yao Y, Xing Z. Methods and clinical development of adenovirus-vectored
738 vaccines against mucosal pathogens. *Mol Ther - Methods Clin Dev* 2016; **3**: 16030.
- 739 23 Lavelle EC, Ward RW. Mucosal vaccines - fortifying the frontiers. *Nat Rev Immunol*
740 2021; : 1–15.
- 741 24 Stylianou E, Paul MJ, Reljic R, McShane H. Mucosal delivery of tuberculosis vaccines: a
742 review of current approaches and challenges. *Expert Rev Vaccines* 2019; **18**: 1271–84.
- 743 25 Verreck FAW, Tchilian EZ, Vervenne RAW, *et al.* Variable BCG efficacy in rhesus
744 populations: Pulmonary BCG provides protection where standard intra-dermal
745 vaccination fails. *Tuberculosis (Edinb)* 2017; **104**: 46–57.
- 746 26 Xiang Z, Li Y, Cun A, *et al.* Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan
747 Africa. *Emerg Infect Dis* 2006; **12**: 1596–9.
- 748 27 Richardson JS, Abou MC, Tran KN, Kumar A, Sahai BM, Kobinger GP. Impact of
749 Systemic or Mucosal Immunity to Adenovirus on Ad-Based Ebola Virus Vaccine Efficacy
750 in Guinea Pigs. *J Infect Dis* 2011; **204**: S1032–42.
- 751 28 Colloca S, Barnes E, Folgiori A, *et al.* Vaccine Vectors Derived from a Large Collection of
752 Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. *Sci*
753 *Transl Med* 2012; **4**: 115ra2-115ra2.
- 754 29 Zhu F-C, Guan X-H, Li Y-H, *et al.* Immunogenicity and safety of a recombinant
755 adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a
756 randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 2020; **396**: 479–88.
- 757 30 Behr MA, Divangahi M, Schurr E. Lessons From Bacille Calmette-Guérin for SARS-
758 CoV-2 Vaccine Candidates. *J Infect Dis* 2021; **223**: 189–91.
- 759 31 Silver RF, Zukowski L, Kotake S, *et al.* Recruitment of antigen-specific Th1-like
760 responses to the human lung following bronchoscopic segmental challenge with purified

761 protein derivative of *Mycobacterium tuberculosis*. *Am J Respir Cell Mol Biol* 2003; **29**:
762 117–23.

763

764 **Figure legends**

765 **Figure 1. Trial profile**

766 PPD: purified protein derivative; LD: low dose aerosol; HD: high dose aerosol; IM-intramuscular
767 injection; PFU: plaque-forming unit

768 **Figure 2. Induction of multifunctional T cells in the airways following aerosol or** 769 **intramuscular vaccination**

770 **A)** Frequencies of airways antigen-specific combined total cytokine-producing CD4 T cells at
771 various timepoints in LD aerosol, HD aerosol and IM cohorts. **B)** Frequencies of airways single
772 cytokine-producing CD4 T cells at various timepoints in LD aerosol cohort. **C)** Frequencies of
773 airways single cytokine-producing CD4 T cells at various timepoints in HD aerosol cohort. **D)**
774 Frequencies of airways antigen-specific combined total cytokine-producing CD8 T cells at various
775 timepoints in LD aerosol, HD aerosol and IM cohorts. **E)** Representative dotplots of airways CD4
776 and CD8 T cells expressing IFN γ , TNF α and IL-2 at wk2 from LD aerosol participants. **F)**
777 Frequencies of airways polyfunctional (triple/3+, double/2+ and single/1 cytokine-positive)
778 antigen-specific CD4 and CD8 T cells at various timepoints in LD aerosol group. **G)** Median
779 proportions displayed in pie chart of antigen-specific airways CD4 and CD8 T cells expressing a
780 specific single or combination of two or three cytokines at various timepoints in LD aerosol group.

781 **Figure 3. Induction of airway tissue-resident memory T cells (T_{RM}) following aerosol or** 782 **intramuscular vaccination**

783 **A)** Representative dotplots of airways antigen-specific CD4 and CD8 T_{RM} at wk2 in LD aerosol
784 participants. **B)** Frequencies of airways antigen-specific IFN γ +CD4 T_{RM} co-expressing CD69 and
785 CD103 surface markers at various timepoints in LD aerosol, HD aerosol and IM vaccine cohorts.
786 **C)** Frequencies of airways antigen-specific IFN γ +CD8 T_{RM} co-expressing CD69 and CD103 at
787 various timepoints in LD aerosol, HD aerosol and IM vaccine cohorts. **D)** Comparison of
788 frequencies of airways antigen-specific CD4 and CD8 T_{RM} co-expressing CD69 and CD103 at

789 8wk post-LD and HD aerosol vaccination. **E)** Representative dotplots of peripheral blood antigen-
790 specific IFN γ +CD4 T cells expressing CD49d at wk2 from LD aerosol participants, and
791 frequencies of circulating antigen-specific CD4 T cells expressing CD49d at various timepoints in
792 LD aerosol, HD aerosol and IM vaccine cohorts. **F)** Representative dotplots of airways antigen-
793 specific IFN γ +CD4 T cells expressing CD49d at wk2 from LD aerosol participants, and
794 frequencies of airways antigen-specific CD4 T cells expressing CD49d at various timepoints in
795 LD aerosol, HD aerosol and IM vaccine cohorts. **G)** Comparison of frequencies of airways
796 antigen-specific IFN γ +CD4 T cells co-expressing CD49d at the peak timepoint in LD aerosol, HD
797 aerosol and IM vaccine cohorts.

798 **Figure 4. Induction of antigen-specific T cell responses in the peripheral blood following**
799 **aerosol or intramuscular vaccination**

800 **A),B),C)** Antigen-specific cytokine production in whole blood culture at various timepoints post-
801 LD aerosol, HD aerosol and IM vaccine groups. The measurements were subtracted from
802 unstimulated control values. **D)** Frequencies of peripheral blood antigen-specific combined total
803 cytokine-producing CD4 T cells at various timepoints in LD aerosol, HD aerosol and IM cohorts.
804 **E)** Frequencies of peripheral blood polyfunctional (triple/3+, double/2+ and single/1 cytokine-
805 positive) antigen-specific CD4 T cells at various timepoints in LD aerosol, HD aerosol and IM
806 vaccine groups. **F)** Frequencies of peripheral blood antigen-specific combined total cytokine-
807 producing CD8 T cells at various timepoints in LD aerosol, HD aerosol and IM groups. **G)**
808 Frequencies of peripheral blood polyfunctional (triple/3+, double/2+ and single/1 cytokine-
809 positive) antigen-specific CD8 T cells at various timepoints in LD aerosol, HD aerosol and IM
810 groups.

811

812 **Supplementary Figure 1. Inhaled aerosol device set-up**

813 The Aeroneb® Solo Micropump was used as part of the delivery device set-up.

814 **Supplementary Figure 2. Respiratory function and bronchoalveolar cellular responses**
815 **following aerosol or intramuscular vaccination**

816 **A), B)** Lung function was assessed as FEV₁ and FVC at baseline and 2wk post-LD aerosol, HD
817 aerosol or IM vaccination. **C), D), F)** Frequencies of differential cells including macrophages,
818 lymphocytes, neutrophils and epithelial cells in BALF from LD aerosol, HD aerosol and IM
819 vaccine cohorts.

820 **Supplementary Figure 3. Induction of multifunctional T cells specific for Ag85A or a cocktail**
821 **of mycobacterial antigens in the airways following aerosol or intramuscular vaccination**

822 **A), B)** Frequencies of airways Ag85A-specific polyfunctional (triple/3+, double/2+ and single/1
823 cytokine-positive) CD4 and CD8 T cells at various timepoints in HD aerosol group. **C)**
824 Frequencies of airways combined total cytokine-producing CD4 T cells specific for *M.tb*
825 CF/rAg85A at various timepoints in LD aerosol, HD aerosol and IM cohorts. **D)** Frequencies of
826 airways polyfunctional (triple/3+, double/2+ and single/1 cytokine-positive) CD4 T cells specific
827 for *M.tb* CF/rAg85A at various timepoints in LD aerosol group. **E)** Median proportions displayed
828 in pie chart of *M.tb* CF/rAg85A-specific airways CD4 T cells expressing a specific single or
829 combination of two or three cytokines at various timepoints in LD aerosol group. **F)** Frequencies
830 of airways combined total cytokine-producing CD8 T cells specific for *M.tb* CF/rAg85A at various
831 timepoints in LD aerosol, HD aerosol and IM cohorts.

832 **Supplementary Figure 4. Transcriptomic analysis of alveolar macrophages (AM) following**
833 **LD aerosol vaccination**

834 **A)** Principal component analysis (PCA) of gene expression in AM obtained before (wk0) and after
835 (wk8) LD aerosol vaccination cultured with (S) or without (US) stimulation. **B)** Venn diagram
836 comparing all DEGs in pairwise comparison. **C)** Significantly enriched functional categories of
837 biological processes by GO associated with DEGs shared between the baseline (wk0) Group 3/1
838 and aerosol vaccine (wk8) Group 4/2. **D)** Venn diagram comparing up- and down-regulated DEGs
839 in pairwise comparison. Heatmap shows DEG uniquely up- and down-regulated, in stimulated
840 aerosol (Group 4) AM. **E)** Significantly enriched functional categories of biological processes by
841 GO associated with uniquely up-regulated DEGs in stimulated aerosol (Group 4) AM.

842 **Supplementary Figure 5. Induction of multifunctional T cells specific for Ag85A or a cocktail**
843 **of mycobacterial antigens in the peripheral blood following aerosol or intramuscular**
844 **vaccination**

845 **A)** Median proportions displayed in pie chart of peripheral blood Ag85A-specific CD4 T cells
846 expressing a specific single or combination of two or three cytokines at various timepoints in LD
847 aerosol and IM vaccine groups. **B)** Frequencies of peripheral blood *M.tb* CF/rAg85A-specific
848 combined total cytokine-producing CD4 T cells at various timepoints in LD aerosol, HD aerosol
849 and IM cohorts. **C)** Frequencies of peripheral blood *M.tb* CF/rAg85A-specific polyfunctional
850 (triple/3+, double/2+ and single/1 cytokine-positive) CD4 T cells at various timepoints in LD
851 aerosol, HD aerosol and IM vaccine groups. **D)** Frequencies of peripheral blood *M.tb* CF/rAg85A-
852 specific polyfunctional (triple/3+, double/2+ and single/1 cytokine-positive) CD8 T cells at various
853 timepoints in LD aerosol, HD aerosol and IM vaccine groups.

854 **Supplementary Figure 6. Impact of pre-existing anti-AdHu5 antibodies on the**
855 **immunogenicity induced by LD aerosol and IM AdHu5Ag85A vaccination**

856 **A)** Correlation plot of pre-existing anti-Ad5 neutralizing antibodies versus pre-existing anti-Ad5
857 total IgG antibody titers in the blood of all trial participants. **B)** Correlation plot of pre-existing
858 anti-Ad5 neutralizing antibodies versus pre-existing anti-Ad5 total IgG antibody titers in the
859 airways of all trial participants. **C)** Correlation plot of pre-existing anti-Ad5 neutralizing antibodies
860 versus peak airways antigen-specific total cytokine+ CD4 T cell responses in LD aerosol vaccine
861 group. **D)** Correlation plot of pre-existing anti-Ad5 neutralizing antibodies versus peak airways
862 antigen-specific total cytokine+ CD8 T cell responses in LD aerosol vaccine group. **E)** Correlation
863 plot of pre-existing anti-Ad5 neutralizing antibodies versus peak peripheral blood antigen-specific
864 total cytokine+ CD4 T cell responses in IM vaccine group. **F)** Correlation plot of pre-existing anti-
865 Ad5 neutralizing antibodies versus peak peripheral blood antigen-specific total cytokine+ CD8 T
866 cell responses in IM vaccine group.




Figure 1 Trial profile




Figure 2 Induction of multifunctional T cells in the airways following aerosol or intramuscular vaccination




Figure 3 Induction of airway tissue-resident memory T cells (T_{RM}) following aerosol or intramuscular vaccination




Figure 4 Induction of antigen-specific T cell responses in the peripheral blood following aerosol or intramuscular vaccination




Figure S1 Inhaled aerosol delivery device set-up




Figure S2 Respiratory function and bronchoalveolar cellular responses following aerosol or intramuscular vaccination







Figure S3 Induction of multifunctional T cells specific for Ag85A or a cocktail of mycobacterial antigens in the airways following aerosol or intramuscular vaccination




A



B



C



D




Figure S5 Induction of multifunctional T cells specific for Ag85A or a cocktail of mycobacterial antigens in the peripheral blood following aerosol or intramuscular vaccination




Figure S6 Impact of pre-existing anti-AdHu5 antibodies on the immunogenicity induced by LD aerosol and IM AdHu5Ag85A vaccination

Table 1 Demographics of participants

	Low dose Aerosol 1x10⁶ N=11	High dose Aerosol 2x10⁶ N=12	IM 1x10⁸ N= 9
Male	2 (18%)	3 (25%)	7(78%)
Female	9 (82%)	9 (75%)	2 (22%)
Years (age)	26 (21-37)	26 (18-38)	27 (18-42)
BMI (Kg/m ²)	24.1 (17.2-35.1)	21.9 (18-30.9)	24.9 (20.1-31.3)
BCG vaccination history			
Participant Recall	7 (64%)	5 (41.6%)	3 (33.3%)
Vaccination Record	1 (9%)	3 (25%)	1 (11%)
Continent of Birth			
Asia	6 (54.5%)	5 (41.6%)	4 (44.4%)
Europe	1 (9%)	1 (8.3%)	2 (22.2%)
America	1 (9%)	2 (16.6%)	3 (33.3%)
Middle East	2 (18.2%)	2 (16.6%)	0
India	1 (9%)	2 (16.6%)	0
Spirometry			
% predicted FEV1	100% (96-126)	99% (89-114)	106% (81-129)
% predicted FVC	98% (82-130)	101% (93-122)	108% (90-130)
Median baseline SpO ₂	99% (97-100)	99% (98-100)	98% (97-100)

Table 2 Characterization of aerosol device and aerosol droplets

Parameters measured	
Nebulizer fill volume	0.5 ml saline
Time to complete nebulization via tidal breathing N=8 (4 male & 4 female adults)	149.25 ± 8.0 (seconds)
Emitted dose at mouth determined with salbutamol sulphate with vaccine using breath simulator (Vt 500 ml, 15bpm) N=4	48.8 ± 2.22%
Aerodynamic droplet size determined with salbutamol sulphate with vaccine by using the Next Generation Impactor (NGI) N=4	<5.39 µm: 85.2 ± 2.04%; 2.08-5.39 µm: 68.0 ± 1.99%
Vaccine viability determined by viral plaque forming unit assay (average value of two experiments)	17.4%

Table 3 Adverse events

Adverse event	Low dose (n=11)	%	High dose (n=12)	%	IM (n=9)	%
Injection site reaction						
Local pain	n/a	n/a	n/a	n/a	0	0
Redness	n/a	n/a	n/a	n/a	1	11.1
Swelling	n/a	n/a	n/a	n/a	1	11.1
Cough	2	18.1	2	16.6	4	44.4
Runny nose	3	27.7	2	16.6	2	22.2
Fatigue	4	36.3	3	25.0	3	33.3
Myalgia	3	27.7	0	0	0	0
Headache	3	27.7	7	58.3	2	22.2
Joint pain	1	9.0	0	0	1	11.1
Chest pain	1	9.0	0	0	0	22.2
Sneezing	1	9.0	1	8.3	2	0
Sinus pain	1	9.0	0	0	0	0
Abdominal pain	1	9.0	1	8.3	1	11.1
Shortness of breath	0	0	1	8.3	0	0
Nose bleed	1	9.0	0	0	0	0
Itchy throat	0	0	1	8.3	0	0
Shivers	2	18.1	0	0	0	0
Dizziness	0	0	0	0	2	22.2

Table 4 Anti-Ad5 antibody titers before and after LD aerosol, HD aerosol, and IM vaccination

Sample	Ad5 humoral immunity	Study time (wk)		LD aerosol		HD aerosol		IM
			N		N		N	
Serum	Anti-Ad5 Total IgG titre	0	11	9513 (700, 115520)	11	5695 (932, 39080)	9	14257 (4974, 67200)
		4	11	4974 (611, 326600)	11	9384* (1161, 68960) P=0.0010	9	20350* (5744, 61200) P=0.0017
	Ad5 neutralizing antibody titre	0	11	22 (2, 7937)	11	130 (2, 7519)	9	203 (2, 11110)
		4	11	32 (3, 7692)	11	134 (2, 7634)	9	2311* (25, 19231) P=0.0039
BALF	Anti-Ad5 Total IgG titre	0	11	469 (222, 2855)	11	522 (84, 3441)	9	281 (24, 3290)
		8	10	502 (115, 1188)	3	213 (98, 859)	3	147 (84, 194)
	Ad5 neutralizing antibody titre	0	11	2.13 (1, 55)	11	13 (1, 93)	9	5.9 (1-139)
		8	10	2.8 (1, 46)	3	14 (1-79)	3	6.4 (1-30)